TLR7 and hepatitis B virus infection: TLR7 agonists have been actively studied in phase 1 and 2 trials aiming to curb the persistent viral load in HIV‐ and HBV‐infected individuals.129 Moreover, various prodrug (pharmacologically active after metabolism) approaches have also targeted TLR7 (RO6870868 [single prodrug] or RO6864018 [double prodrug]), and use of these as TLR7 agonists was useful in treating hepatitis B infection in phase 1 clinical trials.